Ablynx is granted GLP certificate for new GLP unit
Having received this GLP certificate, Ablynx's GLP unit will be able to seamlessly carry out pre-clinical analytical testing and pharmacokinetics studies in-house, to the required regulatory standard.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "Being awarded the GLP certificate from the Belgian authorities confirms our commitment to consistently perform at a high standard in this stringent regulatory environment. This is an important milestone for Ablynx as we continue to grow towards a product-based company. With this certificate, we no longer solely rely on third parties to carry out the pre-clinical GLP testing for our programmes. This enables us to retain more control on quality, timing and associated costs."
Most read news
Other news from the department politics & laws
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.